SEC filings
AbbVie (ABBV)
Recent filings AbbVie made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0001551152All filings on SEC.gov
10-QQuarterly report
Quarterly report
AbbVie reported $49.4 billion in worldwide net revenues for the nine months ended September 30, 2026, up 11% on a reported basis, with operating earnings of $16.7 billion and diluted earnings per share of $4.79. …
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Jennifer L. Davis, a Class II director of AbbVie, notified AbbVie's board on October 28, 2026 that she intends to resign effective November 2, 2026, following her appointment as Chief Executive Officer of Align Technology. …
8-KCurrent report
Results of Operations and Financial Condition
AbbVie reported third-quarter 2026 net revenues of $17.404 billion, up 10.3%, with GAAP diluted EPS of $2.37 and adjusted diluted EPS of $3.82, and raised its full-year 2026 adjusted diluted EPS guidance to $13.95–$13.99 while announcing a…
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
AbbVie expanded its board of directors from twelve to thirteen members and appointed Dr. John M. Carethers as a Class II director on October 14, 2026. …
8-KCurrent report
Results of Operations and Financial Condition
AbbVie said its third-quarter 2026 earnings will include $216 million of pre-tax acquired IPR&D and milestones expense, an unfavorable $0.11 impact on both GAAP and adjusted non-GAAP diluted earnings per share, and revised its 2026…
8-KCurrent report
Regulation FD Disclosure
AbbVie completed its acquisition of Apogee Therapeutics for $135.11 per share in cash, an equity value of roughly $10.9 billion, with Apogee now part of AbbVie and its stock delisted from Nasdaq. AbbVie CEO Robert A. …
8-KCurrent report
Other Events
AbbVie completed an underwritten public offering of nine series of senior notes totaling roughly $10 billion in aggregate principal, and expects to use the net proceeds to fund a portion of the cash consideration for its previously…
8-KCurrent report
Other Events
As part of financing its acquisition of Apogee Therapeutics, AbbVie entered an underwriting agreement with Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. …
10-QQuarterly report
Quarterly report
AbbVie reported worldwide net revenues of $32.0 billion for the six months ended June 30, 2026, up 11% on a reported basis, with operating earnings of $10.4 billion, diluted earnings per share of $2.42 and cash flows from operations of…
8-KCurrent report
Results of Operations and Financial Condition
AbbVie reported second-quarter 2026 net revenues of $16.990 billion and GAAP diluted EPS of $2.03, and said it agreed to acquire Apogee Therapeutics at a total equity value of approximately $10.9 billion. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow AbbVie in Readster
Add AbbVie to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.